Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Years' Resolutions

This article was originally published in RPM Report

Executive Summary

If a panel of analysts are correct, the coming year will bring the reintroduction of Biogen-Idec's Tysabri, approval of Merck's human papilloma virus vaccine Gardasil and a continued stalemate over generic biologics. We asked top pharmaceutical analysts to weigh in on the events they think will move the market in 2006.

You may also be interested in...



Borderline Insanity? Drug Importation May Get New Life in 2007

After receding into political obscurity for several years, drug importation has come back into focus on Capitol Hill. The chances for legislation getting through Congress and past a presidential veto are a long shot, but Wall Street is worried.

Borderline Insanity? Drug Importation May Get New Life in 2007

After receding into political obscurity for several years, drug importation has come back into focus on Capitol Hill. The chances for legislation getting through Congress and past a presidential veto are a long shot, but Wall Street is worried.

Wall Street Looks Ahead: Market-Moving Events that Will Shape 2007

Wall Street analysts are confident that Congress will pass drug safety legislation this year, but in a poll conducted by The RPM Report, they didn't agree on much else. The panel was split most other questions-from whether Congress would remove the "non-interference" clause under Medicare Part D to whether FDA would approve another cox-2 inhibitor.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel